Immuno-Biological Laboratories Co., Ltd.
4570.T
Get informed when a big investor buys or sells
+ FollowMarket Cap$9.98B
Close$
Share Statistics
| Market cap | $9.98 Billion |
|---|---|
| Enterprise Value | $9.25 Billion |
| Dividend Yield | $6.00 (0.56%) |
| Earnings per Share | $35.33 |
| Beta | -0.02 |
| Outstanding Shares | 9,313,458 |
Return
| Return on Equity | 19.51% |
|---|---|
| Return on Assets | 16.55% |
| Return on Invested Capital | 18.16% |
Valuation & Multiples
| P/E Ratio | 27.11 |
|---|---|
| PEG | 42.04 |
| Price to Sales | 9.32 |
| Price to Book Ratio | 5.31 |
| Enterprise Value to Revenue | 8.57 |
| Enterprise Value to EBIT | 26.46 |
| Enterprise Value to Net Income | 25 |
| Total Debt to Enterprise | 0.02 |
| Debt to Equity | 0.09 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 7, 2026
EPS Estimate
-
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationNext Earnings Call
Expected Date
November 11, 2026
EPS Estimate
-
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About Immuno-Biological Laboratories Co., Ltd.
54 employees
CEO: Tsutomu Seito Immuno-Biological Laboratories Co., Ltd. (IBL) is a global entity dedicated to the research, development, production, and distribution of immunological reagents. The company's diverse offerings include ELISA assay kits designed for the p...